Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        11-20 of 409 results

        Refine search

        Research

        A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)

        V114 (15-valent pneumococcal conjugate vaccine [PCV]) contains all serotypes in 13-valent PCV (PCV13) and additional serotypes 22F and 33F. This study evaluated safety and immunogenicity of V114 compared with PCV13 in healthy infants, and concomitant administration with DTPa-HBV-IPV/Hib and rotavirus RV1 vaccines. ...

        Research

        Acute Flaccid Paralysis in Australian Children from 2007 to 2017

        Acute flaccid paralysis (AFP) surveillance continues globally as part of the World Health Organization's goal to eradicate poliomyelitis. The Australian Paediatric Surveillance Unit, Paediatric Active Enhanced Disease Surveillance network, and National Enterovirus Reference Laboratory collaborate in AFP surveillance in Australia, capturing and reviewing cases of AFP for all aetiologies in order to exclude poliovirus. We aimed to describe the AFP epidemiology in childhood over an 11 year period. ...

        Research

        Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

        Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active. ...

        Research

        Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

        As part of the accelerated development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we report a dose-finding and adjuvant justification study of SCB-2019, a protein subunit vaccine candidate containing a stabilised trimeric form of the spike (S)-protein (S-Trimer) combined with two different adjuvants. ...

        Research

        ATAGI 2021 annual statement on immunisation Last updated: 19 September 2021

        Christopher Blyth CC MBBS (Hons) DCH FRACP FRCPA PhD Director, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases ...

        Research

        Childhood vaccination coverage in Australia: an equity perspective

        This study describes trends in social inequities in first dose measles-mumps-rubella (MMR1) vaccination coverage in Western Australia (WA) and New South Wales (NSW). ...

        Research

        Postvaccination Febrile Seizure Severity and Outcome

        Vaccine-proximate febrile seizures accounted for a small proportion of all febrile seizures hospital presentations ...

        Research

        Intraseason decline in influenza vaccine effectiveness during the 2016 southern hemisphere influenza season: A test-negative design study and phylogenetic assessment

        Overall, the 2016 influenza vaccine showed good protection against laboratory-confirmed infection among general practice patients ...

        Research

        Vaccine hesitancy, refusal and access barriers: The need for clarity in terminology

        We propose more precision in the term 'vaccine hesitancy' is needed particularly since much under-vaccination arises from factors related to access ...

        Research

        Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study

        Immune responses after the initial vaccination persisted for the 12 months studied, with little additional response after the booster dose at 6 months ...

        Page 2 of 41